This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed the most recent trading day at $67.54, moving -1.03% from the previous trading session.
Encouraging Near-Term Outlook for Medical Services Industry
by Urmimala Biswas
With growing importance of effective healthcare management, the medical service industry is becoming an integral part of the modern healthcare mechanism.
CareDx (CDNA) in Focus: Stock Moves 9.8% Higher
by Zacks Equity Research
CareDx (CDNA) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: First Western, CBIZ, BioTelemetry, Expeditors International and Core-Mark
by Zacks Equity Research
The Zacks Analyst Blog Highlights: First Western, CBIZ, BioTelemetry, Expeditors International and Core-Mark
Zacks Market Edge Highlights: Tesla, BioTelemetary, Amazon, Booking and Nike
by Zacks Equity Research
Zacks Market Edge Highlights: Tesla, BioTelemetary, Amazon, Booking and Nike
Investing in the Innovation Winners
by Tracey Ryniec
If only an investor could buy companies that were on the cutting edge. How do you find those stocks?
U.S. Service Sector Humming: 5 Solid Buys
by Tirthankar Chakraborty
The non-manufacturing index comes in at 59.7 in February, topping analysts' estimates of 57.3. It also sees uninterrupted expansion for the 109th consecutive month.
BioTelemetry (BEAT) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 33.33% and 0.57%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
BioTelemetry (BEAT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed at $76.01 in the latest trading session, marking a -0.38% move from the prior day.
BioTelemetry (BEAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTelemetry (BEAT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, BioTelemetry (BEAT) closed at $73.52, marking a +0.05% move from the previous day.
BioTelemetry (BEAT) Upgraded to Buy: Here's Why
by Zacks Equity Research
BioTelemetry (BEAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioTelemetry (BEAT) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed at $72.34 in the latest trading session, marking a +0.72% move from the prior day.
ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
ResMed (RMD) benefits from growth at CER across all geographies. However, device sales in France and Japan get affected.
NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y
by Zacks Equity Research
NextGen (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q3; strong fiscal 2019 view buoys optimism.
Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally
by Zacks Equity Research
Solid overseas growth boosts Varian's (VAR) fiscal Q1 results.
PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong
by Zacks Equity Research
PetMed (PETS) sees reorder sales growth in Q3. Rising competition forced the company to offer additional discounts to customers in the quarter which had a negative impact on the gross margin.
Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid
by Zacks Equity Research
Within Structural Heart, growth is driven by several product areas across Abbott's (ABT) broad portfolio.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioTelemetry (BEAT) closed at $67.50, marking a +0.42% move from the previous day.
Top Ranked Momentum Stocks to Buy for January 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
Teladoc Expands Services with Virtual Back Pain Treatment
by Zacks Equity Research
Teladoc's (TDOC) new addition of virtual back pain treatment will broaden its suite of products and services.
BioTelemetry (BEAT) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does BioTelemetry (BEAT) have what it takes to be a top stock pick for momentum investors? Let's find out.
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed the most recent trading day at $68.16, moving -1.91% from the previous trading session.
Is BioTelemetry (BEAT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?